Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer

Dr Mabel Mardones - Rocky Mountain Cancer Centers, Denver, USA
Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer ( Dr Mabel Mardones - Rocky Mountain Cancer Centers, Denver, USA )
10 Jun 2026

Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC

Dr Bjorn Henning Gronberg - Norwegian University of Science and Technology, Trondheim, Norway
Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC ( Dr Bjorn Henning Gronberg - Norwegian University of Science and Technology, Trondheim, Norway )
10 Jun 2026

Amivantamab plus pembrolizumab and carboplatin in R/M HNSCC: Evaluating improved response and survival vs chemo

Dr Barbara Burtness - Yale School of Medicine, New Haven, USA
Amivantamab plus pembrolizumab and carboplatin in R/M HNSCC: Evaluating improved response and survival vs chemo ( Dr Barbara Burtness -  Yale School of Medicine, New Haven, USA )
9 Jun 2026

Talazoparib plus enzalutamide improves radiographic progression-free survival in HRR-altered mCSPC

Dr Neeraj Agarwal - University of Utah, Salt Lake City, USA
Talazoparib plus enzalutamide improves radiographic progression-free survival in HRR-altered mCSPC ( Dr Neeraj Agarwal - University of Utah, Salt Lake City, USA )
9 Jun 2026

Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic triple-negative breast cancer

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic triple-negative breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )
9 Jun 2026

Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )
9 Jun 2026

1: Safe administration and dosing of EGFR inhibitors in NSCLC - Practical guidance for oncology nurses

Helena Ullgren, Rachel Powell, Irati Rodriguez-Matesanz and Elin Backman Stålnacke
1: Safe administration and dosing of EGFR inhibitors in NSCLC - Practical guidance for oncology nurses ( Helena Ullgren, Rachel Powell, Irati Rodriguez-Matesanz and Elin Backman Stålnacke )
8 Jun 2026

Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety

Dr Atsuo Takashima - National Cancer Center Hospital, Tokyo, Japan
Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety ( Dr Atsuo Takashima - National Cancer Center Hospital, Tokyo, Japan )
1 Jun 2026

ASCO 2026: Latest in prostate cancer

Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel Merseburger
ASCO 2026: Latest in prostate cancer ( Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel Merseburger )
1 Jun 2026

Amivantamab in HPV-unrelated mHNSCC gives high response rates after immunotherapy and chemo

Dr Barbara Burtness - Yale Cancer Center, New Haven, USA
Amivantamab in HPV-unrelated mHNSCC gives high response rates after immunotherapy and chemo ( Dr Barbara Burtness -  Yale Cancer Center, New Haven, USA )
1 Jun 2026

Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission

Dr Robert Stein - University College London, London, UK
Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission ( Dr Robert Stein - University College London, London, UK )
1 Jun 2026

MCED blood test trial fails primary end point, but screening cut number of cancers found at stage IV

Dr Peter Sasieni - Queen Mary University of London, London, UK
MCED blood test trial fails primary end point, but screening cut number of cancers found at stage IV ( Dr Peter Sasieni - Queen Mary University of London, London, UK )
1 Jun 2026